The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer

Molecular Biology Reports

Volumn 39, Issue 1, 2012, Pages 375-380

  Koç, Esin ^a   Caner, Vildan ^a   Büyükpınarbaşılı, Nur ^b   Tepeli, Emre ^a   Türk, Nilay Şen ^a   Ozan Cetin G ^a   Bağcı, Gülseren ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b Yedikule Teaching Hospital   (Turkey)

Author keywords

ERCC1; Non small cell lung cancer; Real time PCR; Single nucleotide polymorphism

Indexed keywords

MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DNA EXTRACTION; DNA REPAIR; EXCISION REPAIR CROSS COMPLEMENTING GROUP 1 GENE; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONCOGENE; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

EID: 84855189095     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0748-8     Document Type: Article

References (34)

1. World Health Organization (2009) Fact Sheet no: 297. http://www.who.int/ cancer/en. Accessed Feb 2009
2. Ministry of Health Republic of Turkey (2009) Cancer statistics in Turkey. http://www.kanser.gov.tr. Accessed Dec 2010
3. DA Ahlquist 2010 Molecular detection of colorectal neoplasia Gastroenterology 138 2127 2139 20420950 10.1053/j.gastro.2010.01.055 1:CAS:528:DC%2BC3cXms1yitbk%3D
4. L Da Silva SR Lakhani 2010 Pathology of hereditary breast cancer Mod Pathol 23 46 51 10.1038/modpathol.2010.37
5. LR Chirieac S Dacic 2010 Targeted therapies in lung cancer Surg Pathol Clin 3 71 82 20680095 10.1016/j.path.2010.04.001
6. JH Hoeijmakers 2001 Genome maintenance mechanisms for preventing cancer Nature 411 366 374 11357144 10.1038/35077232 1:CAS:528:DC%2BD3MXktVSjs74%3D (Pubitemid 32467046)
7. SC Shuck EA Short JJ Turchi 2008 Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology Cell Res 18 64 72 18166981 10.1038/cr.2008.2 1:CAS:528:DC%2BD1cXitl2qug%3D%3D
8. CH Park T Bessho T Matsunaga A Sancar 1995 Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease J Biol Chem 270 22657 22660 7559382 10.1074/jbc.270.39.22657 1:CAS:528:DyaK2MXosFOqtL0%3D
9. LJ Niedernhofer H Odijk M Budzowska E van Drunen A Maas AF Theil, et al. 2004 ERCC1-XPF is required to resolve DNA interstrand cross-link-induced double-strand breaks Mol Cell Biol 24 5776 5787 15199134 10.1128/MCB.24.13.5776- 5787.2004 1:CAS:528:DC%2BD2cXls1aqtro%3D (Pubitemid 38787963)
10. M Cummings K Higginbottom GJ McGurk OG Wong B Köberle RT Oliver, et al. 2006 XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair Biochem Pharmacol 72 166 175 16756962 10.1016/j.bcp.2006.04.025 1:CAS:528:DC%2BD28Xls1altbo%3D (Pubitemid 43870167)
11. CJ Park BS Choi 2006 The protein shuffle. Sequential interactions among components of the human nucleotide excision repair pathway FEBS J 273 1600 1608 16623697 10.1111/j.1742-4658.2006.05189.x 1:CAS:528:DC%2BD28XksFWrtr8%3D (Pubitemid 43779814)
12. D Isla C Sarries R Rosell G Alonso M Domine M Taron, et al. 2004 Single nucleotide polymorphisms and outcome in docetaxel cisplatin treated advanced NSCLC Ann Oncol 8 1194 1203 10.1093/annonc/mdh319 (Pubitemid 39199306)
13. W Zhou G Liu S Park Z Wang JC Wain TJ Lynch 2005 Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer Cancer Epidemiol Biomarkers Prev 14 491 496 15734977 10.1158/1055-9965.EPI-04-0612 1:CAS:528:DC%2BD2MXhs1GhsLY%3D (Pubitemid 40270116)
14. S Zienolddiny D Campa H Lind D Ryberg V Skaug L Stageland, et al. 2006 Polymorphisms of DNA repair genes and risk of non-small lung cancer Carcinogenesis 27 560 567 16195237 10.1093/carcin/bgi232 1:CAS:528: DC%2BD28XhvVeltL8%3D (Pubitemid 43372885)
15. T Takenaka T Yano C Kiyohara N Miura H Kouso T Ohba, et al. 2009 Effects of Excision Repair Cross-Complementation Group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients Lung Cancer 67 101 107 10.1016/j.lungcan.2009.03.007
16. JJ Yu KB Lee C Mu Q Li TV Abernathy, et al. 2000 Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene Int J Oncol 16 555 560 10675489 1:CAS:528:DC%2BD3cXhsF2murg%3D
17. P Chen J Wiencke K Aldape A Kesler-Diaz R Miike K Kelsey, et al. 2000 Association of an ERCC1 polymorphism with adult-onset glioma Cancer Epidemiol Biomarkers Prev 9 843 847 10952103 1:CAS:528:DC%2BD3cXmsVWjtbg%3D (Pubitemid 30660059)
18. Travis WD, Brambilla E, Müller-Hermelink HK, Haris CC (2004) Tumours of the lung. In: World Health Organization Classification of Tumours: Pathology and Genetics-Tumours of Lung, Pleura, Thymus, and Heart. Lyon, pp 10-11
19. L Cheng MR Spitz WK Hong Q Wei 2000 Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis Carcinogenesis 21 1527 1530 10910954 10.1093/carcin/21.8.1527 1:CAS:528:DC%2BD3cXlvVeqsbY%3D (Pubitemid 30601644)
20. MR Spitz QY Wei Q Dong CI Amos XF Wu 2003 Genetic susceptibility to lung cancer: the role of DNA damage and repair Cancer Epidemiol Biomarkers Prev 12 689 698 12917198 1:CAS:528:DC%2BD3sXmt1elsr0%3D (Pubitemid 36993157)
21. Butkiewicz D, Rusin M, Sikora B, Lach A, Chora̧ży M (2010) An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer. Mol Biol Rep. doi: 10.1007/s11033-010-0674- 1
22. W Zhou S Gurubhagavatula G Liu S Park DS Neuberg JC Wain, et al. 2004 Excision Repair Cross-Complementation Group 1 polymorphism predicts overall survival in advanced NSCLC patients treated with platinum-based chemotherapy Clin Cancer Res 10 4939 4943 15297394 10.1158/1078-0432.CCR-04-0247 1:CAS:528:DC%2BD2cXmtlSitr4%3D (Pubitemid 39099767)
23. C Tibaldi E Giovannetti E Vasile V Mey AC Laan S Nannizzi, et al. 2008 Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine-cisplatin treated advanced NSCLC patients Clin Cancer Res 14 1797 1803 18347182 10.1158/1078-0432.CCR-07-1364 1:CAS:528:DC%2BD1cXjtleju78%3D (Pubitemid 351469466)
24. C Kiyohara K Yoshimasu 2007 Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis Int J Med Sci 4 59 71 17299578 1:CAS:528:DC%2BD2sXms1KrsrY%3D (Pubitemid 46238636)
25. Q Wei L Cheng C Amos 2000 Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study J Natl Cancer Inst 92 1764 1772 11058619 10.1093/jnci/92.6.440 1:CAS:528:DC%2BD3cXot1SltLs%3D
26. G Matullo AM Dunning S Guarrera C Baynes S Polidoro S Garte, et al. 2006 DNA repair polymorphisms and cancer risk in non-smokers in a cohort study Carcinogenesis 27 997 1007 16308313 10.1093/carcin/bgi280 1:CAS:528: DC%2BD28XjslKrsrg%3D
27. A Kalikaki M Kanaki H Vassalou J Souglakos A Voutsina V Georgoulias, et al. 2009 DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small cell lung cancer Clin Lung Cancer 10 118 123 19362955 10.3816/CLC.2009.n.015 1:CAS:528:DC%2BD1MXltFers7k%3D
28. C Garnis WW Lockwood E Vucic Y Ge L Girard JD Minna, et al. 2006 High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH Int J Cancer 118 1556 1564 16187286 10.1002/ijc.21491 1:CAS:528:DC%2BD28XhslCqsLk%3D
29. IA Yang V Relan CM Wright MR Davidson KB Sriram SM Savarimuthu Francis, et al. 2011 Common pathogenic mechanisms and pathways in the development of COPD and lung cancer Expert Opin Ther Targets 15 439 456 21284573 1:CAS:528:DC%2BC3MXivFWhtrY%3D
30. H Kitamura T Yazawa K Okudela H Shimoyamada H Sato 2008 Molecular and genetic pathogenesis of lung cancer: differences between small-cell and non-small-cell carcinomas Open Pathol J 2 106 114 10.2174/1874375700802010106 1:CAS:528:DC%2BD1cXhtlOnsb3N
31. A Kalikaki A Koutsopoulos M Trypaki J Souglakos E Stathopoulos V Georgoulias, et al. 2008 Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC Br J Cancer 99 923 929 19238633 10.1038/sj.bjc.6604629 1:CAS:528:DC%2BD1cXhtV2jurrP
32. H Linardou IJ Dahabreh D Bafaloukos P Kosmidis S Murray 2009 Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC Nat Rev Clin Oncol 6 352 366 19483740 10.1038/nrclinonc.2009.62 1:CAS:528: DC%2BD1MXms12gtLc%3D
33. GJ Riely KA Politi VA Miller W Pao 2006 Update on epidermal growth factor receptor mutations in non-small cell lung cancer Clin Cancer Res 12 7232 7241 17189394 10.1158/1078-0432.CCR-06-0658 1:CAS:528:DC%2BD28XhtlCrsbfF (Pubitemid 46095394)
34. SW Han TY Kim YK Jeon PG Hwang SA Im KH Lee, et al. 2006 Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation Clin Cancer Res 12 2538 2544 16638863 10.1158/1078-0432.CCR-05- 2845 1:CAS:528:DC%2BD28XjvValu7o%3D